Article Figures & Data
Figures
- Fig. 1.
RT-PCR and Northern analyses of p36 and p11. A, RT-PCR of p36 in individual normal prostate (1–4 and 6 from cancer-free biopsy specimens; and 5 from organ donor) and prostate cancer-derived total RNA. HPRT was used to indicate comparable RNA loading. B, Northern analysis of p36 in individual normal prostate (1–3 from cancer-free biopsy specimens; 4 and 5 from organ donors) and prostate cancer-derived total RNA. Ethidium bromide-stained 18S rRNA indicates comparable RNA loading. C, RT-PCR of p11 in individual normal prostate (same as p36) and prostate cancer-derived total RNA. Three PCR cycles (21, 24, and 27) were used, and there was no statistically significant difference in the intensity of PCR products between normal prostate and prostate cancer. Depicted are products with 24 PCR cycles.
- Fig. 2.
p36 and p11 protein expression in prostate tissues. Depicted in each row are consecutive sections stained with H&E (first column), p36 antibody (second column), p11 antibody (third column), and 34βE12 Ab (fourth column). A–D, glands from peripheral zone of an organ donor (×20); E–H, BPH from transurethral resection (×20), I–L, cancer from radical prostatectomy (×20); M–P, p36/p11 negative PIN from radical prostatectomy (×40); Q–T, p36/p11 positive PIN (×40).
- Fig. 3.
CpG map of p36 gene. Vertical lines above bar indicate the relative position of the CpG sites. Nucleotide position below the bar is based on the sequence from GenBank (Accession no. AC019146). The orientation of genomic DNA is reverse complimentary to p36 cDNA.
- Fig. 4.
5-Azacytine reactivation of p36 gene expression in LNCaP cells. RT-PCR was used to determine p36 expression using RNA isolated from (1) prostate cancer, (2) normal prostate, (3) blood, (4) DU145 cells, and (5) LNCaP cells treated with and (6) without 5 azacytidine.
Volume 61, Issue 17
